Annual report pursuant to Section 13 and 15(d)

Consolidated Statements Of Cash Flows

v3.22.0.1
Consolidated Statements Of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash Flows from Operating Activities:      
Net loss $ (16,158) $ (16,829) $ (17,855)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:      
Depreciation and amortization 400 499 982
Provision for bad debts (202) 1,328 1,695
Provision for sales returns 0 87 0
Provision for inventory excess and obsolescence (275) (591) 413
Inventory disposals and recoveries, net (122) 1,300 15
Amortization of discount on lines of credit 159 165 140
Amortization of debt issuance costs 356 331 188
Patent litigation mark-to-market 315 0
Change in fair value of warrants 0 (5,850)
Issuance Of Restricted Shares 164 0
Issuance costs for common stock warrants 0 1,641
Stock-based compensation 1,662 3,370 2,742
Gain on debt forgiveness (3,014)
Warrants issued to consultants 0 0 48
Deferred income taxes 0 0 7
Earned interest income 0 0 2
Changes in operating assets and liabilities:      
Accounts receivable (978) 4,286 655
Inventory (1,375) (871) 825
Prepaid expenses and other current assets 285 825 439
Accounts payable and accrued liabilities 1,765 (2,107) (3,156)
Deferred revenue 308 (379) 114
Net cash and cash equivalents used in operating activities (16,710) (12,795) (12,746)
Cash Flows from Investing Activities:      
Purchases of property, plant, and equipment (707) (96) (207)
Net cash and cash equivalents used in investing activities (707) (96) (207)
Cash Flows from Financing Activities:      
Proceeds from the issuance of common stock and June 2020 Warrants 14,420 6,912 9,171
Proceeds from the issuance of Series F Convertible Preferred Stock 0 2,700
Proceeds from the issuance of July 2020 Warrants 0 15,300
Payments of equity offering costs (1,135) (1,281) (821)
Payment of July 2020 Warrant issuance costs 0 (1,640)
Borrowings on other long-term loans 0 3,140
Borrowings under term loan 0 0 2,500
Principal payment on term loan 0 (700)
Borrowings on credit facility 0 3,000
Payments of credit facility 0 (3,000)
Payments of debt issuance costs (25) (128) (133)
Proceeds from the exercise of common stock warrants 16,562 46
Proceeds from exercise of stock options 132 0 4
Net cash and cash equivalents provided by financing activities 29,954 24,349 10,721
Effect of exchange rate changes (238) 317 (23)
Increase (decrease) in cash and cash equivalents 12,299 11,775 (2,255)
Cash, cash equivalents and restricted cash, beginning of year 17,876 6,101 8,356
Cash, cash equivalents and restricted cash, end of year 30,175 17,876 6,101
Supplemental cash flow disclosure:      
Cash paid for interest 1,771 1,881 1,784
Cash received for interest 56 11
Cash paid for income taxes 171 22 35
Cash paid for operating leases 246 489 797
Non-cash accrual for capital expenditures 0 0 18
Non-cash settlement of performance award liability 510 151 201
Non-cash right-of-use assets obtained in exchange for lease obligations 48 2,037 276
Equity financing costs in accounts payable 0 74 129
Deemed dividend on preferred stock 546 17,378
Forgiveness of debt 0 10
Receivable from warrants exercised and included in prepaid and other current assets (1,498) 1,498
Warrants issued in connection with debt instruments $ 0 $ 67 $ 161